Form 4: Ventyx Biosciences Director Allison Hulme Granted 40,000 Stock Options

Ventyx Biosciences, Inc. Director Allison Hulme was granted 40,000 stock options with an exercise price of $2.25, aligning her interests with the company's long-term performance.

Summary

• Allison Hulme, a Director of Ventyx Biosciences, Inc. (VTYX), was granted 40,000 stock options.
• The stock options have an exercise price of $2.25 per share.
• These options were acquired on June 5, 2025, and are exercisable from the same date.
• The options are for 40,000 shares of Ventyx Biosciences' Common Stock.
• The expiration date for these stock options is June 5, 2035.
• The shares subject to the option will vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the day prior to the next Annual Meeting of the Issuer's stockholders, contingent on Ms. Hulme's continued service as a Service Provider under the Issuer's 2021 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options to a director is a standard practice that aligns management's interests with shareholders, indicating a commitment to long-term value creation. It is a routine compensation event, not indicative of extraordinary positive or negative news.

Positives

• The grant of stock options to Director Allison Hulme aligns her financial interests directly with the long-term performance and shareholder value creation of Ventyx Biosciences.
• Equity compensation is a standard practice for incentivizing directors and retaining talent, promoting commitment to the company's success.

Future Outlook

The vesting schedule for the granted stock options, tied to continued service, indicates an expectation of Allison Hulme's ongoing involvement and contribution to Ventyx Biosciences' strategic direction and governance.

Industry Context

The granting of stock options to directors is a common and widely accepted practice within the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align leadership incentives with shareholder returns.

Comparison to Industry Standards

• The structure of this option grant, including the vesting conditions tied to service and annual meetings, is consistent with typical equity compensation plans observed across publicly traded companies in the life sciences sector.
• While specific grant sizes vary by company size, stage, and individual role, the use of stock options with a defined exercise price and vesting schedule is a standard mechanism for director remuneration, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) in their early growth phases, which heavily utilize equity to attract and retain talent.

Stakeholder Impact

• Shareholders: The grant of options can be seen as a positive step towards aligning director incentives with shareholder value, though it represents potential future dilution if options are exercised.
• Director (Allison Hulme): Receives a significant equity incentive, tying her personal financial success to the company's stock performance.

Next Steps

• The stock options will vest according to the specified conditions (one-year anniversary of grant or day prior to next Annual Meeting), subject to continued service.
• Upon vesting, Allison Hulme will have the right to exercise the options and purchase Ventyx Biosciences common stock at the exercise price of $2.25 per share.

Key Dates

Recommendation

Keywords

Ventyx Biosciences, VTYX, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Beneficial Ownership